BBPWM
ARQT icon

Blue Bell Private Wealth Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Blue Bell Private Wealth Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-369
Closed -$8.69K – 719
2026
Q1 		$8.69K Hold
369
– – ﹤0.01% 578
2025
Q4 		$10.7K Hold
369
– – ﹤0.01% 551
2025
Q3 		$6.96K Buy
369
+129
+54% +$2.03K ﹤0.01% 575
2025
Q2 		$3.37K Hold
240
– – ﹤0.01% 606
2025
Q1 		$3.75K Buy
+240
New +$3.38K ﹤0.01% 598

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Blue Bell Private Wealth Management's ARQT Position: Q2 2026 in Review

Blue Bell Private Wealth Management sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 369 shares — an estimated $8.69K sold.

Blue Bell Private Wealth Management first reported a position in ARQT in Q1 2025 and held it in 5 quarters. The position peaked at $10.7K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Blue Bell Private Wealth Management reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Blue Bell Private Wealth Management sold 369 Arcutis Biotherapeutics shares in Q2 2026, an estimated $8.69K.
  • Blue Bell Private Wealth Management first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 5 quarters.
  • Blue Bell Private Wealth Management's Arcutis Biotherapeutics position peaked at $10.7K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Blue Bell Private Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.